论文部分内容阅读
目的探讨卵巢上皮性癌(简称卵巢癌)p53和cerbB2表达的临床意义。方法用免疫组织化学法检测p53和cerbB2,结合临床病理及肿瘤的生物学行为进行分析。结果p53在高分化卵巢癌中的表达频率显著低于中、低分化癌,p53表达阳性组的卵巢癌对化疗不敏感,其预后亦明显劣于阴性组卵巢癌。卵巢癌的cerbB2表达与临床期别、组织学类型和分级、残余瘤大小、化疗疗效和预后均无显著相关性。结论p53是评价卵巢癌化疗耐药性和预后的可靠指标。
Objective To investigate the clinical significance of p53 and cerbB2 expression in epithelial ovarian cancer (Ovarian cancer). Methods The expression of p53 and cerbB2 was detected by immunohistochemistry. The clinicopathological features and the biological behavior of tumor were analyzed. Results The frequency of p53 expression in well-differentiated ovarian cancer was significantly lower than that in moderate and poorly differentiated carcinoma. The ovarian cancer with p53 positive expression was not sensitive to chemotherapy and the prognosis was also significantly lower than that in negative ovarian cancer. The expression of cerbB2 in ovarian cancer had no significant correlation with clinical stage, histological type and grade, size of residual tumor, curative effect and prognosis of chemotherapy. Conclusion p53 is a reliable indicator to evaluate the drug resistance and prognosis of ovarian cancer.